UBS Group raised its price objective for CVS Health to $115.00 from $100.00.
The investment bank maintained its buy rating on the stock.
The new target represents a potential 20.2% upside from the previous closing price.
The revision follows a recent upgrade to a Zacks Rank #2 (Buy).
Analysts cite improved earnings optimism and a strong market position for the pharmacy operator.